Statins and Oxidative Stress During Atherogenesis

European Journal of Preventive Cardiology

Volumn 10, Issue 3, 2003, Pages 181-189

  Norata, Giuseppe D ^a   Pirillo, Angelo ^a   Catapano, Alberico L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale Bassini   (Italy)

Author keywords

atherogenesis; oxidative stress; statins

Indexed keywords

ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN B; ATORVASTATIN; FLUINDOSTATIN; GEMFIBROZIL; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CHOLESTEROL SYNTHESIS; CYTOTOXICITY; DISEASE COURSE; HUMAN; HYPERTENSION; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SMOKING; SMOOTH MUSCLE FIBER; CONCENTRATION RESPONSE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; IN VITRO STUDY; OXIDATION; VASCULAR ENDOTHELIUM;

ANTIOXIDANTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OXIDATIVE STRESS;

EID: 0037672472     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000071772.88247.14     Document Type: Article

References (131)

1. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–1791.
2. Scandinavian Simvastatin Survival Study Group Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The long term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. N Engl J Med 1998; 339: 1349–1357.
4. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–120.
5. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76: 333–337.
6. Weinstein DB, Carew TE, Steinberg D. Uptake, and degradation of low-density lipoprotein by swine arterial smooth muscle cells with inhibition of cholesterol biosynthesis. Biochem Biophys Acta 1976; 424: 404–421.
7. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983; 52: 223–261.
8. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophages degradation of low density lipoprotein previously incubated with cultured endothelial cells: Recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci USA 1981; 78: 6499–6503.
9. Henriksen T, Mahoney EM, Steinberg D. Interactions of plasma lipoproteins with endothelial cells. Ann NY Acad Sci 1982; 401: 102–116.
10. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophages degradation of biologically modified low-density lipoprotein. Arteriosclerosis 1983; 3: 149–159.
11. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low-density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low-density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883–3887.
12. Morel DW, DiCorleto PE, Chisolm GM. Endothelial, and smooth muscle cells alter low-density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984; 4: 357–364.
13. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785–1792.
14. Steinberg D. Oxidized low-density lipoprotein: An extreme example of lipoprotein heterogenicity. Isr J Med Sci 1996; 32: 469–472.
15. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, et al. Atherosclerosis: Basic mechanism: Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488–2496.
16. Henriksen T, Evensen SA, Carlander B. Injury to human endothelial cells induced by low-density lipoproteins. Scand J Clin Lab Invest 1979; 39: 361–368.
17. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983; 3: 215–222.
18. Pirillo A, Norata GD, Zanelli T, Catapano AL. Over expression of HSP70i in COS-1 cells fails to protect from the cytotoxicity of Ox-LDL. Arterioscler Thromb Vasc Biol 2001; 21: 348–354.
19. Escargueil-Blanc I, Salvayre R, Nègre-Salvayre A. Necrosis, and apoptosis induced by oxidized low-density lipoproteins occur through two calcium-dependent pathways in lymphoblastoid cells. FASEB J 1994; 8: 1075–1080.
20. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth cells derived from normal vessel and coronary atherosclerotic plaques. J Clin Invest 1995; 95: 2266–2274.
21. Björkerud B, Björkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol 1996; 16: 416–424.
22. Hughes H, Mathews B, Lenz ML, Guyton JR. Cytotoxicity of oxidized LDL to porcine smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb Vasc Biol 1994; 14: 1177–1185.
23. Nishio E, Arimura S, Watanabe Y. Oxidized LDL induces apoptosis in cultured smooth muscle cells: A possible role for 7-ketocholesterol. Biochem Biophys Res Commun 1996; 223: 413–418.
24. Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury‘ hypothesis. Circulation 1997; 95: 1760–1763.
25. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K. Oxidized low-density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 1998; 273: 9681–9687.
26. Lizard G, Deckert V, Dubrez L, Moisant M, Gambert P, Lagrost L. Induction of apoptosis in endothelial cells treated with cholesterol oxides. Am J Pathol 1996; 148: 1625–1638.
27. Haunstetter A, Izumo S. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82: 1111–1129.
28. Lehr HA, Becker M, Marklund SL, Hubner C, Arfors KE, Kohlschutter A, et al. Superoxide-dependent stimulation of leukocyte adhesion by oxidatively modified LDL in vivo. Arterioscler Thromb 1992; 12: 824–829.
29. Ohlsson BG, Englund MC, Karlsson AL, Knusten E, Erixon C, Skribeck H, et al. Oxidized low-density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kB to DNA and the subsequent expression of tumour necrosis factor-α and interleukin-1ß in macrophages. J Clin Invest 1996; 98: 78–89.
30. Cominacini L, Garbin U, Fratta PA, Paulon T, Davoli A, Campagnola M, et al. Lacidipine inhibits the activation of the transcription factor NF-kB and the expression of adhesion molecules induced by pro-oxidant signals. J Hypertens 1997; 15: 1633–1640.
31. Maziere C, Auclair M, Djavaheri-Mergny M, Packer L, Maziere JC. Oxidized low-density lipoprotein induces activation of the transcription factor NF-kB in fibroblast, endothelial, and smooth muscle cells. Biochem Mol Biol Int 1996; 39: 1201–1207.
32. Wung BS, Cheng JJ, Hsieh HJ, Shyy YJ, Wang DL. Cyclic strain-induced monocyte chemotactic protein-1 gene expression in endothelial cells involves reactive oxygen species activation of activator protein-1. Circ Res 1997; 81: 1–7.
33. Roebuck KA, Rahman A, Lakshminarayanan V, Janakidevi K, Malik AB. H2O2 and tumour necrosis factor alpha activate intracellular adhesion molecule-1 gene transcription trough distinct cis-regulatory elements within the ICAM-1 promoter. J Biol Chem 1995; 270: 18966–18974.
34. Collins T. Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 5: 499–508.
35. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Cir Res 1999; 85: 753–766. This paper identifies a number of genes that are induced by oxidative stress in the vascular wall; many of which are common to those induced by oxidised LDL.
36. Kamanna VS, Pai R, Ha H, Kirschenbaum MA, Roh DD. Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney International 1999; 55(6): 2192–2202.
37. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Rigoni A, et al. The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity. Cell Adhes Comm 1999; 7: 223–231. The anti-diabetic drug reduces the activation of endothelial cells.
38. Li D, Mehta JL. Antisense to Lox-1 inhibits oxidized LDL-mediated up regulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101: 2889–2895. This paper shows that in endothelial cells the effects of oxidised LDL are dependent upon the interaction with a specific receptor.
39. Eligini S, Colli S, Basso F, Sironi L, Tremoli E. Oxidized low-density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 1719–1725.
40. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 2640–2647.
41. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993–998.
42. Roma P, Catapano AL. Stress proteins and atherosclerosis. Atheroscler 1996; 127: 147–154.
43. Zhu WM, Roma P, Pellegatta F, Catapano Al. Oxidized-LDL induce the expression of heat shock protein 70 in human endothelial cells. Biochem Biophys Res Commun 1994; 200: 389–394.
44. Zhu WM, Roma P, Pirillo A, Pellegatta F, Catapano AL. Oxidized-LDL induce hsp 70 expression of heat shock protein 70 in human smooth muscle cells. FEBS Letters 1995; 372: 1–5.
45. Yamaguchi M, Sato I, Bannai S. Induction of stress protein in mouse peritoneal macrophages by oxidized low-density lipoprotein. Biochem Biophys Res Commun 1993; 193: 1198–1201.
46. Frostegard J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protein in monocytic cells by oxidized low-density lipoprotein. Atherosclerosis 1996; 121: 93–103.
47. Zhu WM, Roma P, Pirillo A, Pellegatta F, Catapano AL. Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating. Arterioscler Thromb Vasc Biol 1996; 9: 1104–1111.
48. Yla-Herttuala S, Palinski W, Rosenfeld ME, Steinberg D, Witzum JL. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J 1990; 11: 88–99.
49. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesions from rabbit and man. J Clin Invest 1989; 84: 1086–1095.
50. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988; 241: 215–218.
51. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10: 336–349.
52. Norata GD, Tonti L, Roma P, Catapano AL. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: A possible role for oxidized LDL. Nutr Metab Cardiovasc Dis 2002; 12: 297–305.
53. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low-density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20(10): 2243–2247.
54. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95: 1062–1071.
55. Kuhn H, Chan L. The role of 15-lipoxygenase in atherogenesis: Pro- and anti-atherogenic actions. Curr Opin Lipidol 1997; 8: 111–117.
56. Henriksson P, Hamberg M, Diczfaluzy U. Formation of 15-HETE as a major hydroxyeicosatetraenoic acid in the atherosclerotic vessel wall. Biochim Biophys Acta 1985; 834: 272–274.
57. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioja T, Witzum JL, et al. Gene expression in macrophage-rich human atherosclerotic lesions: 15-lipoxygenase and acetyl LDL receptor mRNA co-localize with oxidation-specific lipid-protein adducts. J Clin Invest 1991; 87: 1146–1152.
58. Tardif JC, Cote G, Lesperance J, Bourassa M, Lambert J, Doucet S, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Groups. N Eng J Med 1997; 337: 365–372.
59. Lonn EM, Yusuf S. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data. Can J Cardiol 1997; 13: 957–965.
60. Bjorkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991; 11(1): 15–22.
61. Catapano AL, Tragni E. Antioxidants, and coronary artery disease. Curr Atheroscl Rep 1999; 1: 221–229.
62. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998; 138: 271–280.
63. Corsini A, Maggi FM, Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9–27.
64. Catapano AL. Calcium antagonists and atherosclerosis. Experimental evidence. Eur Heart J 1997; 18(Suppl A): 80–86.
65. Aruoma OI, Smith C, Cecchini R, Evans PJ, Halliwell B. Free radical scavenging and inhibition of lipid peroxidation by beta-blockers and by agents that interfere with calcium metabolism. A physiologically significant process? Biochem Pharmacol 1991; 42: 735–743.
66. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992; 13: 341–390.
67. Schuh J, Fairclough GF, Hashemeyer RH. Oxygen-mediated heterogenicity of apo low-density lipoprotein. Proc Natl Acad Sci USA 1978; 75: 3173–3177.
68. Lenz ML, Hughes H, Mitchell JR, Via DP, Guyton JR, Taylor AA, et al. Lipid hydroperoxy and hydroxy derivatives in copper-catalysed oxidation of low-density lipoprotein. J Lipid Res 1990; 31: 1043–1050.
69. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun 1989; 6: 67–75.
70. Jurgens G, Hoff HY, Chisolm GM, Esterbauer H. Modification of human serum low-density lipoprotein by oxidation-characterization and pathophysiological implications. Chem Phys Lipids 1987; 45: 315–336.
71. Esterbauer H, Jurgens G, Quehenberger O, Koller E. Auto-oxidation of human low-density lipoprotein: Loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28: 495–509.
72. Schuh J, Novogrodsky A, Hashemeyer RH. Inhibition of lymphocyte mitogenesis by auto-oxidized low-density lipoprotein. Biochem Biophys Res Commun 1978; 84: 763–768.
73. Ahotupa M, Marniemi J, Lehtimaki T, Talvinen K, Raitakari OT, Vasankari T, et al. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem 1998; 31: 257–261.
74. Patrono C, Fitzgerald GA. Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309–2315.
75. Helbock HJ, Beckman KB, Shigenaga MK, Walter PB, Woodall AA, Yeo HC, et al. DNA oxidation matters: The HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. Proc Natl Acad Sci USA 1998; 95: 288–293.
76. Chan SS, Monteiro HP, Deucher GP, Abud RL, Abuchalla D, Junqueira VB. Functional activity of blood polymorphonuclear leukocytes as an oxidative stress biomarker in human subjects. Free Rad Biol Med 1998; 24: 1411–1418.
77. de Vries JH, Hollman PC, Meyboom S, Buysman MN, Zock PL, van Staveren WA, et al. Plasma concentrations and urinary excretion of the antioxidant flavonols quercitin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr 1998; 68: 60–65.
78. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Non-lipid related effects of statins. Ann Med 2000; 32(3): 164–176. A comprehensive review of the so-called pleiotropic effects of statins.
79. Aviram M, Dankner G, Cogan U, Hochgraf E, Brook JG. Lovastatin inhibits low-density lipoprotein oxidation and alters fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism 1992; 41: 229–235.
80. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993; 1165: 335–338.
81. Girona J, La Ville AE, Sola R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846–851.
82. Suzumura K, Odawara A, Yasuhara M, Tanaka K, Narita H, Suzuki T. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation. Biolog Pharmaceut Bull 1999; 22: 971–974.
83. Suzumura K, Yasuhara M, Tanaka K, Suzuki T. Protective effects of fluvastatin sodium (XU-63-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 1999; 57: 697–703.
84. Kagota S, Yamaguchi Y, Nakamura K, Kunitomo M. Functional evidence for anti-oxidant action of fluvastatin on low-density lipoprotein using isolated macrophages and aorta. Clin Exp Pharmacol Physiol 2000; 27: 401–405.
85. Obata T, Ebihara A, Yamanaka Y. Fluvastatin, a new inhibitor of 3-hydroxyl-3-methylglutaryl coenzyme A reductase, resists hydroxyl radical generation in the rat myocardium. J Pharmacy Pharmacol 2000; 52: 425–430.
86. Obata T, Yamanaka Y. Protective effect of fluvastatin, a new inhibitor of 3-hydroxyl-3-methylglutaryl coenzyme A reductase, on MPP(+)-induced hydroxyl radical in the rat striatum. Brain Res 2000; 860: 166–169.
87. Yasuhara M, Suzumura K, Tanaka K, Takahashi M, Aoki S, Odawara A, et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolaemic rabbits. Biol Pharmaceut Bull 2000; 23: 570–574.
88. Loop RA, Anthony M, Willis RA, Folkers K. Effects of ethanol, lovastatin and coenzyme Q10 treatment on antioxidants and TBA reactive material in liver of rats. Mol Aspect Med 1994; 15: 195–206.
89. Palomaki A, Malminiemi K, Metsa-Ketela T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Letters 1997; 410: 254–258.
90. Palomaki A, Malminiemi K, Solakivi T, Malminiemi O. Ubiquinone supplementation during lovastatin treatment: Effect on LDL oxidation ex vivo. J Lipid Res 1998; 39: 1430–1437.
91. Leonhardt W, Kurktschiev T, Meissner D, Lattke P, Abletshauser C, Weidinger G, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low-density lipoproteins and trace metals. Eur J Clin Pharmacol 1997; 53: 65–69.
92. Hussein O, Schlezinger S, Rosenblat M, Keidar S, Aviram M. Reduced susceptibility of low-density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypercholesterolaemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11–18.
93. Sanchez-Quesada JL, Otal-Entraigas C, Franco M, Jorba O, Gonzales-Sastre F, Blanco-Vaca F, et al. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolaemia. Am J Cardiol 1999; 84: 655–659.
94. Yoshida H, Ishikawa T, Ayaori M, Shige H, Hosoai H, Nishio E, et al. Effects of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolaemia: A pilot study. Clin Therap 1995; 17: 379–389.
95. Zambrana JL, Lopez-Miranda J, Blanco A, Arizon JM, Jansen S, Paniagua JA, et al. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlipidaemia. J Heart Lung Transpl 1998; 17: 1213–1219.
96. Martinez-Castelao A, Grinyo JM, Fiol C, Castineiras MJ, Hurtado I, Gil-Vernet S, et al. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolaemic renal transplant patients. Kidney Int 1999; 71: 231–234.
97. Kleinveld HA, Demacker PNM, De Haan AFJ, Stalenhoef AFH Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 1993; 23: 289–295.
98. Hoffman R, Brook GJ, Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies. Atherosclerosis 1992; 93: 105–113.
99. Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61–69. Superoxide decreases the availability of NO, by decreasing superoxide production statin may increase NO at the level of the arterial wall.
100. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolaemia: Anti-atherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol 1998; 31: 39–45.
101. Umetani N, Kanayama Y, Okamura M, Negoro N, Takeda T. Lovastatin inhibits gene expression of type-I scavenger receptor in THP-1 human macrophages. Biochim Biophys Acta 1996; 1303: 199–206.
102. Hrboticky N, Draude G, Hapfelmejr G, Lorenz R, Weber PC. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during early stage of differentiation into macrophages. Arterioscler Thromb Vasc Biol 1999; 19: 1267–1275.
103. Pietsch A, Erl W, Lorenz RL. Lovastatin reduces the expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 1996; 52: 433–439.
104. Leviev I, James R. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON-1 gene activation. Atherosclerosis 2000; 151(1): 41.
105. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON-3) is a high-density lipoprotein-associated lactonase and protects low-density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435–33442.
106. Lehninger AL, Nelson DL, Cox MM. Principles of biochemistry. 2nd edition. New York: Worth Publishers, Inc.; 1993: 669–683.
107. Appelkvist EL, Edlund C, Löw P, Schedin S, Kalen A, Dallner G. Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis. Clin Invest 1993; 71: S97–S102.
108. Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226–229.
109. Laaksonen R, Ojala J-P, Tikkanen MJ, Himberg J-J. Serum ubiquinone concentrations after short- and long-term treatment with HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1994; 46: 313–317.
110. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. For the Atorvastatin Study Group I. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolaemia. Am J Cardiol 1997; 79: 1475–1481.
111. Åberg F, Appelkvist EL, Dallner G, Ernster L. Distribution, and redox state of ubiquinones in rat and human tissues. Arch Biochem Biophys 1992; 295: 230–234.
112. Mohr D, Bowry VW, Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta 1992; 1126: 247–254.
113. de Rijke YB, Bredie SJH, Demacker PNM, Vogelaar JM, Hak-Lemmers HLM, Stalenhoef AFH The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Arterioscler Thromb Vasc Biol 1997; 17: 127–133.
114. Willis RA, Folkers K, Tuccker JL, Ye C-Q, Xia L-J, Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci USA 1990; 87: 8928–8930.
115. Bargossi AM, Battino M, Gaddi A, Fiorella PL, Grossi G, Barozzi G, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A inhibitors. Int J Clin Lab Res 1994; 24: 171–176.
116. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low-density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc Natl Acad Sci USA 1991; 88: 1646–1650.
117. Carr AC, Zhu B-Z, Frei A. Potential anti-atherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res 2000; 87: 349–354.
118. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408–416.
119. Neuzil J, Thomas SR, Stocker R. Requirement for, promotion, or inhibition by alpha-tocopherol of radical-induced initiation of plasma lipoprotein lipid peroxidation. Free Radical Biol Med 1997; 22: 57–71.
120. Bowry VW, Stocker R. Tocopherol-mediated peroxidation: The pro-oxidant effect of vitamin E on radical-initiated oxidation of human low-density lipoprotein. J Am Chem Soc 1993; 115: 6029–6044.
121. Suarna C, Dean RT, May J, Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler Thromb Vasc Biol 1995; 15: 1616–1624.
122. Delbosc S, Morena M, Djouad F, Ledoucen C, Descomps B, Cristol JP. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes. J Cardiovasc Pharmacol 2002; 40: 611–617.
123. Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002; 91: 173–179.
124. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142–147. The pro-oxidant effects of angiotensin II are well known, simvastatin may exert an antioxidant protective effect at the cardiac level by interfering with this pathway.
125. Subbiah MT. Mechanisms of cardio-protection by estrogens. Proc Soc Exp Biol Med 1998; 217: 23–29.
126. Yue TL, Cheng HY, Lysko PG, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exper Ther 1992; 263: 92–98.
127. Jukema JW, Zwindermann AH, van Boven AJ, Reiber JHC, Van der Laarse A, Lie KI, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arter Thromb Vasc Biol 1996; 16: 425–430.
128. Jukema JW, van Boven AJ, Zwinderman AH, Van der Laarse A, Bruschke AV. Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis. Cardiovasc Drugs Ther 1998; 12: 111–118.
129. Orekhov AN, Tertov VV, Sobenin IA, Akhmedzhanov NM, Pivoravova EM. Anti-atherosclerotic and anti-atherogenic effects of calcium antagonist plus statin combination: Amplidipine and lovastatin. Int J Cardiol 1997; 62: S67–S77.
130. Mak IT, Weglicki WB. Comparative antioxidant activities of propanol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 1990; 66: 1449–1452.
131. Vazquez M, Zambon D, Hernandez Y, Adzet T, Merlos M, Ros E, et al. Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients combined hyperlipidaemia. Brit J Clin Pharmacol 1998; 45: 265–269.